Unexplored limitations in a randomized trial that examines efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: comment on the article by Merrill et al.
Arthritis & Rheumatology
論文與作者
Arthritis Rheumatol. 2025;77(8):1108.
Qianyu Guo; Junkang Zhao; Li-Yun Zhang; James Cheng-Chung Wei